Anticorps anti-NR1 dans l'encéphalite anti-récepteur N-méthyl-D-aspartate et la schizophrénie

7Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

The recent discovery of anti-NMDA receptor antibodies and proof of their pathogenic effects in limbic encephalitides raised many questions among neuroscientist and physicians working in the field of schizophrenia. Indeed, this two conditions share several major clinical, pathophysiological or etiological aspects and some authors tend to consider some forms of schizophrenia as mild-encephalitis cases. Some studies have reported the presence of these antibodies in schizophrenic patient's sera without neurological symptoms. These findings suggest new therapeutic perspectives in some schizophrenic patients, despite a low seroprevalence and pathogenic effects that remain to be demonstrated.

Cite

CITATION STYLE

APA

Le Guen, E., Doukhan, R., Hamdani, N., Tamouza, R., Groc, L., Honnorat, J., & Leboyer, M. (2015, January 1). Anticorps anti-NR1 dans l’encéphalite anti-récepteur N-méthyl-D-aspartate et la schizophrénie. Medecine/Sciences. Editions EDK. https://doi.org/10.1051/medsci/20153101014

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free